This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

CytRx Announces Positive Results From Animal Trial With Combination Aldoxorubicin And Doxorubicin Therapy

Stocks in this article: CYTR

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that an in vivo trial investigating aldoxorubicin, its tumor-targeting conjugate of the widely used chemotherapeutic agent doxorubicin, in combination with unconjugated doxorubicin, demonstrated positive results and provided the basis for the Company’s current evaluation of the combination therapy in cancer patients with advanced solid tumors in a Phase 1b clinical trial.

The trial compared the antitumor efficacy and tolerability of weekly intravenous treatments with saline or doxorubicin compared with three dosing regimens of either aldoxorubicin alone or combination aldoxorubicin and doxorubicin in a xenograft model of human pancreatic cancer. As single agents, doxorubicin and aldoxorubicin were administered at their maximum tolerated doses (MTD), while each agent was given at 50% of their MTD when combined. Doxorubicin alone produced only modest tumor inhibition. Aldoxorubicin alone and each combination therapy arm induced both complete and partial remissions, with antitumor efficacy within all arms essentially identical. Importantly, the trial data showed better tolerability for the combination therapy at these low dose levels compared with single agent aldoxorubicin.

The study, “Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model,” Kratz, F., et al., was published in the peer-reviewed International Journal of Pharmaceutics, 441 (2013) pages 499-506.

“The data from this trial are particularly encouraging as pancreatic cancer typically responds poorly to chemotherapy,” said CytRx Executive Vice President and Chief Medical Officer Daniel Levitt, M.D., Ph.D. “The ability of a combined therapy with aldoxorubicin and doxorubicin to demonstrate efficacy in this cancer at doses that were well-tolerated indicates its potential for the treatment of other chemotherapeutic-resistant tumors such as chondrosarcoma and chordomas. The design and rationale behind this trial produced valuable information and we are currently testing this combination in a phase 1b clinical trial in patients with solid tumors. A study abstract has been submitted for presentation at the American Society for Clinical Oncology (ASCO) meeting later this year.”

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs